tiprankstipranks
Trending News
More News >
Agronomics Limited (GB:ANIC)
LSE:ANIC

Agronomics (ANIC) AI Stock Analysis

Compare
115 Followers

Top Page

GB:ANIC

Agronomics

(LSE:ANIC)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 5.2)
Rating:44Neutral
Price Target:
6.00p
▼(-6.25% Downside)
The score is weighed down primarily by weak financial performance (recent losses and persistently negative cash flow), with technicals also bearish (price below key moving averages and negative MACD). Valuation is additionally constrained by a negative P/E driven by losses and no dividend data to offset risk; the main positive is the debt-free balance sheet, though equity has been eroding.
Positive Factors
Strategic Partnerships
The partnership with Nomad Foods enhances market entry strategies for cell-cultivated seafood, strengthening Agronomics' position in sustainable food innovation.
Technological Advancements
The grant for Solar Foods supports the expansion of production capabilities, positioning the company as a leader in clean food technology and enhancing long-term growth potential.
Innovative Product Launch
Launching the first cultivated meat dog treat showcases Agronomics' commitment to innovation and sustainability, tapping into the growing demand for eco-friendly pet food solutions.
Negative Factors
Revenue Volatility
Revenue volatility poses challenges for financial stability, necessitating improved revenue consistency and cost management for sustainable growth.
Negative Cash Flows
Negative cash flows indicate reliance on external financing, which could hinder operational flexibility and long-term financial health if not addressed.
Profitability Challenges
Negative margins highlight profitability issues, requiring strategic initiatives to improve cost efficiency and revenue generation for long-term viability.

Agronomics (ANIC) vs. iShares MSCI United Kingdom ETF (EWC)

Agronomics Business Overview & Revenue Model

Company DescriptionAgronomics Limited is a principal investment firm specializing in investments in funds, equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the alternative proteins company with a focus on cellular agriculture, nascent industry of modern foods, biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Agronomics Limited was founded on May 3, 2011 and is based in Ramsey, Isle of Man.
How the Company Makes MoneyAgronomics Limited makes money through strategic investments in early-stage companies within the cellular agriculture sector. The company's revenue model is primarily based on capital appreciation and returns from equity stakes in these companies. Agronomics often invests in businesses that are pioneering novel food production methods, such as lab-grown meat and alternative proteins, which have the potential to disrupt traditional food industries. The company may also derive income from dividends or interest payments from its investment portfolio. Significant partnerships with leading players in the food technology space and a focus on high-growth potential ventures contribute to its earnings.

Agronomics Financial Statement Overview

Summary
Agronomics Limited faces significant revenue and profit volatility impacting its income statement, scoring 32.0. The balance sheet is strong with zero debt, scoring 78.0, but cash flows are negative, scoring 40.0. Overall, the financial landscape is challenging due to poor income but stable due to a solid balance sheet.
Income Statement
28
Negative
Agronomics Limited shows significant volatility in revenue, with drastic declines in the TTM and recent annual periods. Gross and net margins have turned negative, indicating profitability challenges. The company needs to improve revenue consistency and cost management to achieve sustainable growth.
Balance Sheet
70
Positive
The company maintains a strong balance sheet with zero debt, resulting in a favorable debt-to-equity ratio. High stockholders' equity and cash reserves provide a cushion for financial stability. However, a decreasing equity ratio indicates a need to optimize asset utilization.
Cash Flow
22
Negative
Cash flows remain under pressure, with negative operating cash flow and free cash flow in the latest periods. Dependence on financing activities to cover cash shortfalls suggests a need for better operational cash management to support business activities sustainably.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue-17.64M-11.92M-8.34M29.70M440.32K10.67M
Gross Profit-5.73M0.00-8.34M29.70M440.32K10.67M
EBITDA-20.06M-26.47M0.000.001.50M0.00
Net Income-32.75M-32.75M-10.99M22.37M8.36M1.02M
Balance Sheet
Total Assets124.67M124.67M157.44M170.20M146.40M101.65M
Cash, Cash Equivalents and Short-Term Investments124.62M124.62M12.24M169.87M146.30M101.21M
Total Debt0.000.000.000.000.000.00
Total Liabilities147.60K147.60K166.17K1.95M2.49M1.62M
Stockholders Equity124.52M124.52M157.27M168.26M143.91M100.03M
Cash Flow
Free Cash Flow-2.93M-1.12M-15.86M-23.67M-42.21M-12.17M
Operating Cash Flow-2.93M-1.12M-15.86M-23.67M-42.21M-12.17M
Investing Cash Flow74.86K1.59M892.00K10.02M-20.02M-11.21M
Financing Cash Flow3.43K1.71K1.68K1.01M31.25M71.82M

Agronomics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.40
Price Trends
50DMA
6.86
Negative
100DMA
6.86
Negative
200DMA
7.00
Negative
Market Momentum
MACD
-0.27
Positive
RSI
30.69
Neutral
STOCH
24.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANIC, the sentiment is Negative. The current price of 6.4 is above the 20-day moving average (MA) of 6.29, below the 50-day MA of 6.86, and below the 200-day MA of 7.00, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 30.69 is Neutral, neither overbought nor oversold. The STOCH value of 24.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ANIC.

Agronomics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
67
Neutral
£116.20M34.871.79%3.29%-9.37%
63
Neutral
£924.00M8.578.92%11.00%
62
Neutral
£194.75M10.0916.48%17.93%-16.53%-44.15%
52
Neutral
£16.92M-6.32-14.80%30.40%23.48%
50
Neutral
£500.02M-3.94-14.23%33.10%
44
Neutral
£61.22M-1.81-10.74%-600.00%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:ANIC
Agronomics
5.85
2.00
51.95%
GB:GROW
Molten Ventures
532.50
246.00
85.86%
GB:IPX
Impax Asset Management
160.80
-17.52
-9.83%
GB:IPO
IP Group plc
56.60
5.40
10.55%
GB:MERC
Mercia Asset Management
27.20
0.34
1.27%
GB:EMVC
NetScientific
60.50
6.00
11.01%

Agronomics Corporate Events

Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Agronomics Takes Heavy Write-Downs but Portfolio Wins Key Regulatory and Commercial Milestones
Negative
Dec 30, 2025

Agronomics reported a sharp decline in performance for the year to 30 June 2025, with net asset value per share falling 20% to 12.34 pence and a swing to a £32.7 million net operating loss, driven largely by £25.1 million of net investment losses, adverse foreign exchange movements and significant write-downs, including the full impairment of its £11.9 million stake in Meatable following that company’s voluntary liquidation. Total assets fell to £124.7 million and cash balances dropped to £3.6 million, underscoring tighter financial conditions even as the group continued to support key holdings such as Liberation Bioindustries and SuperMeat through follow-on funding.

Despite the financial hit, the portfolio achieved notable regulatory and commercial milestones that strengthen Agronomics’ strategic position in cellular agriculture, with Meatly securing first-in-world approvals and sales for cultivated pet food in the UK and Europe, Solar Foods listing in Finland and expanding partnerships with Ajinomoto, and All G gaining Chinese regulatory clearance for recombinant bovine lactoferrin. Additional progress included new manufacturing and offtake partnerships for Liberation Bioindustries, expanded collaboration for BlueNalu in European cultivated seafood, and multiple regulatory clearances for alternative proteins and specialty oils, suggesting that while sector funding has tightened and weaker players are being written off, leading assets in Agronomics’ portfolio are edging closer to commercial scale and diversified revenue streams. The company also set 13 February 2026 for its AGM, encouraging shareholders to exercise their voting rights by proxy and engage with management ahead of the meeting.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Agronomics boosts BlueNalu stake with US$6.6m mix of equity and convertible notes
Positive
Dec 30, 2025

Agronomics has deepened its exposure to cultivated seafood pioneer BlueNalu with a US$6 million equity subscription in new preferred shares and a further US$600,000 investment in BlueNalu’s 2025 convertible promissory note round, taking its fully diluted stake to an expected 12.96%. The equity leg of the deal is being settled through the issuance of 30,643,003 new Agronomics ordinary shares at the company’s latest reported net asset value per share, while the CPNs, part of an approximately US$8 million round led by specialist food-tech investors, will convert into preferred stock on favourable terms upon a qualifying fundraise. The new Agronomics shares issued to BlueNalu are subject to a one-year lock-in and orderly market restrictions, and admission of the enlarged share capital to AIM is expected around 7 January 2026, implying modest dilution for existing shareholders but reinforcing Agronomics’ strategic bet on cell-cultivated seafood as BlueNalu advances regulatory engagement, commercial launch preparations for its cultivated bluefin tuna toro, and broader value-chain partnerships.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Agronomics Writes Off Meatable Stake as Cultivated Meat Venture Dissolves
Negative
Dec 19, 2025

Agronomics has announced that its portfolio company Meatable B.V. will be dissolved and all operating activities terminated after the cultivated meat business failed to secure continued funding from existing or new investors. The board and shareholders opted for an orderly wind-down under statutory liquidation procedures, leading Agronomics to write down its £11.9 million carrying value in Meatable to zero, crystallising the loss of its £7.9 million total investment, which represented about 8.1% of its net asset value as of 30 September 2025; despite the setback, the company stressed it remains focused on actively managing and supporting the rest of its portfolio with strong long-term growth prospects.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Agronomics Lifts Stake as Liberation Bioindustries Closes First Tranche of Series A1 Funding
Positive
Dec 19, 2025

Agronomics has strengthened its position in precision fermentation by announcing that portfolio company Liberation Bioindustries has closed the first tranche of its Series A1 equity round, supporting the completion of a 600,000-litre commercial-scale biomanufacturing facility in the US. The plant will produce bio-based proteins and other food ingredients for consumer goods and industrial manufacturers, underpinned by recent partnerships with Vivici to produce dairy protein Vivitein BLG at commercial volumes and with NEOM’s food company Topian to co-develop a fermentation facility in Saudi Arabia. As part of the round, Agronomics has converted all its convertible loan notes into Series A1 shares, increasing its holding from 6,834,147 to 16,538,437 shares, and now carries its total US$27 million investment in Liberation Bioindustries at US$46.8 million, equivalent to about 23% of its last reported net asset value; an affiliate, New Agrarian Company, will also invest US$2.5 million, underscoring Agronomics’ conviction that Liberation’s infrastructure will be a key asset in reshaping ingredient production and bolstering food and supply-chain security.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Agronomics Invests in Sustainable Cultivated Meat with SuperMeat
Positive
Nov 21, 2025

Agronomics Limited has announced a US$ 2 million investment in SuperMeat, a company specializing in cultivated meat, as part of a US$ 3.5 million funding round. This investment will support SuperMeat’s efforts to commercialize its cultivated chicken production in Europe, which is noted for its reduced carbon emissions and cost-efficiency compared to conventional farming. The investment aligns with Agronomics’ strategy to promote sustainable food production, reflecting a strategic shift towards a cleaner and technologically advanced future for food.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Agronomics Reports NAV Growth and Portfolio Milestones
Positive
Nov 13, 2025

Agronomics Limited reported a 1.7% increase in its Net Asset Value (NAV) per share as of September 30, 2025, reaching 14.65 pence, driven primarily by unrealized foreign exchange gains and fair value gains on investments. The company’s portfolio companies have achieved significant milestones, including FDA recognition for Onego Bio’s product and strategic partnerships and approvals for Solar Foods and Clean Food Group, indicating strong commercial progress in the precision fermentation industry.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
EVERY Company Secures $55 Million for U.S. Expansion
Positive
Nov 10, 2025

EVERY Company, a portfolio company of Agronomics Limited, has secured $55 million in Series D funding to expand its manufacturing capacity and scale its operations within the $270 billion egg market. This funding will facilitate EVERY’s nationwide rollout in the U.S., with its precision-fermented egg proteins set to be featured in Walmart stores, providing a sustainable alternative to traditional egg supply chains amid rising egg prices and supply chain disruptions.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Agronomics’ Geltor Achieves FDA GRAS Status for Vegan Collagen
Positive
Oct 21, 2025

Agronomics announced that its portfolio company, Geltor, Inc., has received FDA GRAS status for its PrimaColl® ingredient, marking it as the first biodesigned vegan collagen polypeptide. This milestone allows Geltor to expand into global nutrition and wellness markets, offering a sustainable, animal-free alternative to traditional collagen products. The FDA’s recognition is a significant step for sustainable protein innovation, aligning with Agronomics’ mission to support clean food transitions. PrimaColl® is poised to lead the beauty ingestibles market, valued at $4.2 billion in 2024, with its applications in food, beverage, beauty, and personal care sectors, emphasizing ethical and environmentally responsible production.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026